An acenocoumarol dose algorithm based on a South-Eastern European population

European Journal of Clinical Pharmacology

Volumn 69, Issue 11, 2013, Pages 1901-1907

  Pop, Tudor Radu ^a   Vesa, Ştefan Cristian ^a   Trifa, Adrian Pavel ^a   Crişan, Sorin ^a   Buzoianu, Anca Dana ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Acenocoumarol; Algorithm; CYP2C9; VKORC1

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CYP2C9 GENE; DEEP VEIN THROMBOSIS; DOSE CALCULATION; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ALGORITHM; GENETIC ANALYSIS; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; LEG THROMBOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; ROMANIA; VALIDATION STUDY; VKORC1 GENE;

ACENOCOUMAROL; AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RANDOM ALLOCATION; ROMANIA; VENOUS THROMBOSIS; VITAMIN K EPOXIDE REDUCTASES;

EID: 84886777993     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1551-3     Document Type: Article

References (33)

1. Takahashi H, Wilkinson GR, Padrini R, Echizen H (2004) CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 75(5):376-380. doi: 10.1016/j.clpt.2004.01.007
2. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41(2):89-295. doi: 10.1080/03602530902843483
3. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141[2 Suppl]:e44S-e88S. doi: 10.1378/chest.11-2292
4. Buzoianu AD, Trifa AP, Mureşanu DF, Crişan S (2012) Analysis of CYP2C9*2, CYP2C9*3 and VKORC1-1639 G > A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med 16(12):2919-2924. doi: 10.1111/j.1582-4934.2012.01606.x
5. Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thrombosis Res 120(1):1-10. doi: 10.1016/j.thromres.2006.10.021
6. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42
7. Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210
8. Schalekamp T, Brassé BP, Roijers JFM, Chahid Y, van Geest-Daalderop JHH et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80(1):13-22. doi: 10.1016/j.clpt.2006. 04.006
9. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287(13):1690-1698. doi: 10.1001/jama.287.13.1690
10. Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG et al (2004) The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14(1):27-33
11. Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M et al (2010) Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 66(3):253-260. doi: 10.1007/s00228-009- 0768-7
12. Goodstadt L, Ponting CP (2004) Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 29(6):289-292. doi: 10.1016/j.tibs.2004.04.004
13. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101-110. doi: 10.1097/01.fpc.0000184955.08453.a8
14. Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J (2006) The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 133(2):183-187. doi: 10.1111/j.1365-2141.2006.06007.x
15. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J (1997) Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 126(2):133-136. doi: 10.7326/0003-4819-126-2-199701150- 00006
16. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J et al (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 138(9):714-719
17. Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N, Goldhaber SZ (2004) Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 91(6):1123-1128. doi: 10.1160/TH04-02-0083
18. Brockmöller J, Tzvetkov MT (2008) Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 64(2):133-157. doi: 10.1007/s00228-007-0424-z
19. Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47(9):565-594. doi: 10.2165/00003088-200847090-00002
20. Borobia AM, Lubomirov R, Ramírez E, Lorenzo A, Campos A, Muñoz-Romo R et al (2012) An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in spanish patients with thromboembolic disease. PLoS One 7(7):e41360. doi: 10.1371/journal.pone.0041360
21. Verde Z, Ruiz JR, Santiago C, Valle B, Bandrés F et al (2010) A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 5(6):e11210. doi: 10.1371/journal.pone. 0011210
22. van Schie RMF, Wessels JAM, le Cessie S, de Boer A, Schalekamp T, van der Meer FJM et al (2011) Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 32(15):1909-1917. doi: 10.1093/eurheartj/ehr116
23. Aynacioglu AS, Brockmöller J, Bauer S, Sachse C, Güzelbey P, Ongen Z et al (1999) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48(3):409-415. doi: 10.1046/j.1365-2125.1999.00012.x
24. Wen MS, Lee M, Chen JJ, Chuang HP, Lu LS, Chen CH et al (2008) Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 84(1):83-89. doi: 10.1038/sj.clpt.6100453
25. Arboix M, Laporte JR, Frati ME, Rutllan M (1984) Effect of age and sex on acenocoumarol requirements. Br J Clin Pharmacol 18(4):475-479
26. Loi CM, Vestal RE (1988) Drug metabolism in the elderly. Pharmacol Ther 36:131-149. doi: 10.1016/0163-7258(88)90115-5
27. Tanaka E (1998) In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 23(4):247-255
28. Dreisbach AW, Lertora JJ (2008) The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 4(8):1065-1074. doi: 10.1517/17425255.4.8.1065
29. Husted S, Andreasen F (1977) The influence of age on the response to anticoagulants. Br J Clin Pharmacol 4:559-565
30. Teichert M, van Noord C, Uitterlinden AG, Hofman A, Buhre PN, De Smet PA et al (2011) Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 153(3):379-385. doi: 10.1111/j.1365-2141.2011.08633.x
31. Vreeburg EM, De Vlaam-Schluter GM, Trienekens PH, Snel P, Tytgat GN (1997) Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol 32(10):991-994. doi: 10.3109/00365529709011215
32. de Hoon JN, Thijssen HH, Beysens AJ, Van Bortel LM (1997) No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 44(4):399-401. doi: 10.1046/j.1365-2125. 1997.00600.x
33. van Schie RM, Verhoef TI, Boejharat SB, Schalekamp T, Wessels JA, le Cessie S et al (2012) Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact 27(4):229-234. doi: 10.1515/dmdi-2012-0024